{"filing":{"accession_number":"0001091818-26-000124","cik":"0001310488","ticker":"BFNH","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"bfnh-08142026_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1310488/000109181826000124/bfnh-08142026_8k.htm"},"events":[{"id":27849,"run_id":25423,"accession_number":"0001091818-26-000124","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses multiple governance events: (1) appointment of Scott Mager as General Counsel on 5/19/2026 and as Director on 6/15/2026; (2) appointment of Richard Kaiser as interim CEO on 6/17/2026; and (3) establishment of an Advisory Board with appointments of Stuart Yarbrough and Edward Mathias. While individual appointments could be classified as exec_appointment, the disclosure centers on a comprehensive governance restructuring involving leadership changes (interim CEO appointment), board expansion (new director), and advisory board formation. This is material as it reflects significant changes in the company's leadership and governance structure.","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","ticker":"BFNH","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29549,"accession_number":"0001091818-26-000124","item_number":"8.01","item_title":"VOLUNTARY DISCLOSURE OF OTHER EVENTS","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses multiple governance events: (1) appointment of Scott Mager as General Counsel on 5/19/2026 and as Director on 6/15/2026; (2) appointment of Richard Kaiser as interim CEO on 6/17/2026; and (3) establishment of an Advisory Board with appointments of Stuart Yarbrough and Edward Mathias. While individual appointments could be classified as exec_appointment, the disclosure centers on a comprehensive governance restructuring involving leadership changes (interim CEO appointment), board expansion (new director), and advisory board formation. This is material as it reflects significant changes in the company's leadership and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T19:24:50.002240+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29549,"accession_number":"0001091818-26-000124","item_number":"8.01","item_title":"VOLUNTARY DISCLOSURE OF OTHER EVENTS","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses multiple governance events: (1) appointment of Scott Mager as General Counsel on 5/19/2026 and as Director on 6/15/2026; (2) appointment of Richard Kaiser as interim CEO on 6/17/2026; and (3) establishment of an Advisory Board with appointments of Stuart Yarbrough and Edward Mathias. While individual appointments could be classified as exec_appointment, the disclosure centers on a comprehensive governance restructuring involving leadership changes (interim CEO appointment), board expansion (new director), and advisory board formation. This is material as it reflects significant changes in the company's leadership and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T19:24:50.002240+00:00","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","ticker":"BFNH","filing_date":"2026-08-14"}]}